Is BTIG Now Negative on NeoGenomics (NASDAQ:NEO) After Recent Downgrade?

September 13, 2017 - By Linda Rogers

 Is BTIG Now Negative on NeoGenomics (NASDAQ:NEO) After Recent Downgrade?

Investors sentiment decreased to 1.15 in Q4 2016. Its down 0.10, from 1.25 in 2016Q3. It fall, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.

Creative Planning holds 6,500 shares or 0% of its portfolio. Nicholas Invest Ptnrs Lp holds 229,190 shares or 0.15% of its portfolio. Renaissance Gru Ltd Com reported 0.01% stake. Perkins Cap Incorporated invested 4.98% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Bard Inc has invested 1.15% in NeoGenomics, Inc. (NASDAQ:NEO). Tiaa Cref Investment Mngmt Ltd Liability accumulated 151,808 shares. Granite Partners Ltd Limited Liability Company reported 0.78% stake. 252,820 were accumulated by Blair William & Com Il. Moreover, Cambridge Advisors has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 12,600 shares. Panagora Asset Management Inc reported 106,558 shares stake. Tower Research Capital Limited Liability Corp (Trc) owns 2,219 shares. Jpmorgan Chase And Company has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Rhumbline Advisers accumulated 0% or 57,691 shares. Legal & General Group Pcl accumulated 0% or 13,516 shares. California Pub Employees Retirement Systems reported 91,400 shares or 0% of all its holdings.

Since May 25, 2017, it had 0 insider buys, and 2 selling transactions for $574,394 activity. $25,005 worth of NeoGenomics, Inc. (NASDAQ:NEO) shares were sold by BALLIET JENNIFER.

NeoGenomics (NASDAQ:NEO) Receives a Downgrade

In analysts note revealed to clients on Monday, 11 September, BTIG has just cut their rating for NeoGenomics (NASDAQ:NEO) shares to a Hold.

Investors sentiment decreased to 1.15 in Q4 2016. Its down 0.10, from 1.25 in 2016Q3. It fall, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.

Creative Planning holds 6,500 shares or 0% of its portfolio. Nicholas Invest Ptnrs Lp holds 229,190 shares or 0.15% of its portfolio. Renaissance Gru Ltd Com reported 0.01% stake. Perkins Cap Incorporated invested 4.98% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Bard Inc has invested 1.15% in NeoGenomics, Inc. (NASDAQ:NEO). Tiaa Cref Investment Mngmt Ltd Liability accumulated 151,808 shares. Granite Partners Ltd Limited Liability Company reported 0.78% stake. 252,820 were accumulated by Blair William & Com Il. Moreover, Cambridge Advisors has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 12,600 shares. Panagora Asset Management Inc reported 106,558 shares stake. Tower Research Capital Limited Liability Corp (Trc) owns 2,219 shares. Jpmorgan Chase And Company has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Rhumbline Advisers accumulated 0% or 57,691 shares. Legal & General Group Pcl accumulated 0% or 13,516 shares. California Pub Employees Retirement Systems reported 91,400 shares or 0% of all its holdings.

Since May 25, 2017, it had 0 insider buys, and 2 selling transactions for $574,394 activity. $25,005 worth of NeoGenomics, Inc. (NASDAQ:NEO) shares were sold by BALLIET JENNIFER.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

Among 10 analysts covering NeoGenomics (NASDAQ:NEO), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. NeoGenomics has $11 highest and $8 lowest target. $10.07’s average target is -0.40% below currents $10.11 stock price. NeoGenomics had 16 analyst reports since September 3, 2015 according to SRatingsIntel. TH Capital reinitiated the stock with “Buy” rating in Monday, October 26 report. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Buy” rating by Roth Capital on Friday, May 26. The company was initiated on Thursday, December 15 by Cantor Fitzgerald. On Friday, March 11 the stock rating was initiated by Benchmark with “Buy”. As per Monday, September 11, the company rating was downgraded by BTIG Research. The company was downgraded on Wednesday, July 27 by BTIG Research. The rating was initiated by First Analysis on Tuesday, October 4 with “Overweight”. William Blair maintained NeoGenomics, Inc. (NASDAQ:NEO) on Sunday, September 6 with “Outperform” rating. On Thursday, September 3 the stock rating was maintained by Roth Capital with “Buy”. The company was reinitiated on Wednesday, May 11 by Roth Capital.

The stock increased 0.10% or $0.01 during the last trading session, reaching $10.11. About 292,937 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since September 13, 2016 and is downtrending. It has underperformed by 30.16% the S&P500.

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The company has market cap of $802.61 million. The Firm operates in Laboratory Testing Segment. It currently has negative earnings. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.